Conference Coverage

Early results favor combo IL-15/anti-CD20 in indolent NHL


Key clinical point: An IL-15 receptor super agonist plus rituximab was well tolerated in patients with indolent non-Hodgkin lymphoma.

Major finding: The ALT-803 plus rituximab combination achieved an overall response rate in 52% of patients, a complete response in 43%, and partial response in 10%.

Study details: A phase 1 study of 21 patients with indolent non-Hodgkin lymphoma.

Disclosures: Dr. Fehniger reported research funding from Altor BioScience LLC.

Source: Fehniger TA et al. AACR Annual Meeting, Abstract CT146.



In total, 21 patients were treated: 16 patients had follicular lymphoma, four patients had marginal zone lymphoma, and one patient had small lymphocytic lymphoma. The median prior therapies received was two (range: 1-18) and five patients were treated who were refractory to prior anti-CD20 MAb therapy.

ALT-803 was well tolerated with no dose limiting toxicities or grade 4 or 5 adverse events. No patients discontinued ALT-803 and the recommended phase 2 dose was 20 mcg/kg subcutaneously. Grade 3 adverse events, regardless of attribution to ALT-803, included transient hypertension (14%), anemia (5%), nausea (5%), chills (5%), fever (5%), neutropenia (5%), and hyperglycemia (5%).

“Patients who received [subcutaneous] ALT-803 developed a unique injection site rash reaction that peaked 7-10 days later but resolved typically within 14 days. It was self-limited and resolved on its own,” Dr. Fehniger said.

At the time of the presentation, the best overall response rate was achieved in 11 of 21 patients (52%), with 9 complete responders (43%), and 2 partial responders (10%).

Next Article: